After big spending and hard lobbying, Pfizer eyes new tax home

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to After big spending and hard lobbying, Pfizer eyes new tax home

AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform

November 9, 2015 9:36 AM EST

Leerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.

Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More

Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22

November 9, 2015 7:32 AM EST

Roth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following announced full data from COSMIC-HF at AHA. The large data set was announced jointly by Cytokinetics and global partner Amgen (NASDAQ:... More